A Single Dose Study to Assess the Peak Plasma Concentration of a Microdose of Recombinant Human Placental Alkaline Phosphatase (hRESCAP, Part 1) Followed by a Single Ascending Dose, FIH Study to Assess Safety and Tolerability of hRESCAP (Part 2).

Trial Profile

A Single Dose Study to Assess the Peak Plasma Concentration of a Microdose of Recombinant Human Placental Alkaline Phosphatase (hRESCAP, Part 1) Followed by a Single Ascending Dose, FIH Study to Assess Safety and Tolerability of hRESCAP (Part 2).

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2013

At a glance

  • Drugs Alkaline phosphatase (Primary)
  • Indications Inflammation; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors TNO
  • Most Recent Events

    • 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jul 2013 Microdosing with 0.5 nmol of 14C-labelled hRESCAP was successful, according to an Alloksys Life Sciences media release.
    • 01 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top